Group 2398.png
  • Dosing
  • Dose adjustments

    Dosing

    KISQALI® 400 mg adjuvant dosing schedule*1

     

     

    Group 4961.png

     

    KISQALI® can be added as an adjuvant treatment up to 12 months following ET initiation.1

     

    KISQALI® monitoring requirements1

     

     

    Group 508.png

     

    *KISQALI® is indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage, II and III early breast cancer at high risk of recurrence.1
    **If grade ≥2 abnormalities are observed, more frequent monitoring is recommended.1
    †Correct electrolyte abnormalities prior to and during treatment.1
    ‡Only initiate KISQALI® in patients with QTcF <450 ms. In case of QTcF prolongation during therapy, more frequent assessments are recommended.1
    CBC, complete blood count; ECG, electrocardiogram; eBC, early breast cancer; ET, endocrine therapy; HER2-, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive; LFT, liver function test; LHRH, luteinising hormone-releasing hormone; QTcF, QT interval corrected for Fridericia’s formula; NSAI, non-steroidal aromatase inhibitor

     

    Dose adjustments

    KISQALI® single-strength tablets make down-dosing simple and convenient*1

     

    Screenshot 2025-06-28 at 9.02.41 AM 1.png

     

    NEUTROPENIA

     

    kisqali-metastatic-breast-cancer-neutropenia-table-desktop 1.png

     

    QT PROLONGATION

     

    kisqali-metastatic-breast-cancer-qt-prolongation-table-desktop_0 1.png

     

    INTERSTITIAL LUNG DISEASE/PNEUMONITIS

     

    kisqali-metastatic-breast-cancer-interstitial-lung-disease-table-desktop 1.png

     

    *Dose adjustment for adverse reactions should be made by reducing the number of tablets taken. If dose reduction below 200 mg/day is required, discontinue treatment. KISQALI® dose modification is recommended based on individual safety and tolerability.1
    †Median time to resolution of ≥grade 3 neutropenia was 0.3 months for KISQALI® + NSAI. Median time to resolution of grade ≥3 or 4 ALT/AST elevation was 0.7 months for KISQALI® + NSAI.1

    ALT, alanine transaminase; AST, aspartate aminotransferase; NSAI, non-steroidal aromatase inhibitor; QTcF, QT interval corrected by Fridericia’s formula.

KISQALI® NSS - UAE

PDF
View

References

  1. KISQALI (ribociclib). Prescribing Information.

  2. Slamon DJ, et al. Ther Adv Med Oncol. 2023;15:1–16.